|
|
|
|
Tumour Biol 2010,Aug,01;31(4):321-31; (PMID: 20490964)
[...]The methylation frequency of ten genes in serum of 50 SBCs varied from 10% in FHIT to 74% in RASSF1A. The methylation status of RASSF1A, BRCA1, p16, CDH1, ER, RARbeta2, APC, and DAPK was significantly correlated with [...]
|
|
|
Cell Prolif 2010,Jun,01;43(3):195-206; (PMID: 20546238)
[...] were up-regulated, but genes associated with genetic instability (p53, Rb, BRCA1) were down-regulated in the karyotypically abnormal cells. CONCLUSION: Karyotypically abnormal chHES-3 cells had a more developed capacity for proliferation, resistance to apoptosis[...]
|
|
|
J Natl Cancer Inst 2010,May,19;102(10):680-91; (PMID: 20427433)
[...]Risk assessments fall into two groups: the risk of carrying a mutation in a high-risk gene such as BRCA1 or BRCA2 and the risk of developing breast cancer with or without such a mutation. Knowledge of breast cancer risks, taken together with the risks and benefits of the intervention, is needed to choose an appropriate disease management strategy.[...]
|
|
|
Int J Biochem Cell Biol 2010,May,01;42(5):693-700; (PMID: 20060929)
Estrogen is involved in breast cancer risk, which is increased for BRCA1 mutation carriers, suggesting a role for BRCA1 in estrogen signaling. BRCA1 exerts its function through forming an E3 ubiquitin ligase with [...]
|
|
|
Breast Cancer Res Treat 2010,Apr,01;120(3):593-601; (PMID: 19466541)
To understand the mechanism of transcriptional down-regulation of BRCA1 by promoter methylation, we screened 51 breast cancer cell lines and identified HCC38 as another [...]
|
|
|
Genet Med 2010,Apr,01;12(4 Suppl):S15-38; (PMID: 20393305)
[...]One major difference is that in the United States, Myriad Genetics is the sole provider of genetic testing, because it has sole control of relevant patents for BRCA1 and BRCA2 genes, whereas genetic testing for familial colorectal cancer is available from multiple laboratories.[...]
|
|
|
Magy Onkol 2010,Mar,01;54(1):19-26; (PMID: 20350864)
The two far ends of the age at the diagnosis of breast cancer are the age of younger than 35, and that of older than 70. Most probably, these two groups of patients differ in many ways.[...]
|
|
|
Int J Surg Pathol 2010,Feb,01;18(1):42-7; (PMID: 19372082)
Basal-like (BL) carcinoma, distinguished by the expression of keratins that are a characteristic of myoepithelial cells, is 1 of the 5 distinct subtypes of breast tumors[...]
|
|
|
Eur J Epidemiol 2010,Feb,01;25(2):103-13; (PMID: 20066476)
[...]We assessed reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers with and without breast cancer. Within the frame-work of the HEBON study, 401 BRCA1/2 mutation carriers completed a baseline (1999-2004) and a follow-up questionnaire (2006-2007).[...]
|
|
|
J Clin Oncol 2010,Jan,10;28(2):222-31; (PMID: 19996031) [FULL TEXT AVAILABLE]
PURPOSE: Women with BRCA1/2 mutations inherit high risks of breast and ovarian cancer; options to reduce cancer[...]
|
 1 2 3 4 5 6 7 8 
|
|
